SALT LAKE CITY - Recursion Pharmaceuticals (NASDAQ:RXRX) announced Monday that its investigational drug REC-4881 demonstrated significant polyp reduction in patients with familial adenomatous ...
Recursion Pharmaceuticals (NASDAQ:RXRX) gained 7% on Monday after releasing encouraging Phase 2 results for REC-4881, its investigational therapy for familial adenomatous polyposis (FAP)—a hereditary ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する